REGENXBIO to Participate in Upcoming Investor Conferences

Rhea-AI Summary

REGENXBIO Inc. (Nasdaq: RGNX) has announced its participation in two upcoming investor conferences. The company will be present at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024, at 5:35 p.m. ET, and the Baird 2024 Global Healthcare Conference on September 11, 2024, at 9:40 a.m. ET. Both events will take place in New York, NY.

Investors can access live webcasts of the fireside chats from both conferences through the Investors section of REGENXBIO's website. Archived replays will be available for approximately 30 days after each presentation. This participation in high-profile healthcare conferences suggests REGENXBIO's commitment to engaging with investors and showcasing its developments in the biotechnology sector.

News Market Reaction – RGNX

+1.83%

1 alert

+1.83% News Effect

On the day this news was published, RGNX gained 1.83%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

ROCKVILLE, Md., Aug. 29, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate the following upcoming investor conferences:

Morgan Stanley 22^nd Annual Global Healthcare Conference
Fireside Chat: Thursday, September 5, 2024 at 5:35 p.m. ET
Location: New York, NY

Baird 2024 Global Healthcare Conference 
Fireside Chat: Wednesday, September 11, 2024 at 9:40 a.m. ET
Location: New York, NY

Live webcasts of the fireside chats at the Morgan Stanley and Baird conferences can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of each webcast will be available for approximately 30 days following the presentation.

ABOUT REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' ZOLGENSMA® for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit www.regenxbio.com.

Contacts:

Dana Cormack
Corporate Communications
dcormack@regenxbio.com 

Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-302234421.html

SOURCE REGENXBIO Inc.

FAQ

When is REGENXBIO (RGNX) participating in the Morgan Stanley Global Healthcare Conference?

REGENXBIO (RGNX) is participating in the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, 2024, at 5:35 p.m. ET in New York, NY.

What is the date and time for REGENXBIO's (RGNX) fireside chat at the Baird Global Healthcare Conference?

REGENXBIO's (RGNX) fireside chat at the Baird 2024 Global Healthcare Conference is scheduled for Wednesday, September 11, 2024, at 9:40 a.m. ET in New York, NY.

How can investors access REGENXBIO's (RGNX) conference presentations?

Investors can access live webcasts of REGENXBIO's (RGNX) fireside chats at both conferences through the Investors section of the company's website at www.regenxbio.com.

How long will the archived replays of REGENXBIO's (RGNX) conference presentations be available?

Archived replays of REGENXBIO's (RGNX) conference presentations will be available for approximately 30 days following each presentation on the company's website.